Biopharmaceutical characterisation of ciprofloxacin-metallic ion interactions: Comparative study into the effect of aluminium, calcium, zinc and iron on drug solubility and dissolution by Stojković, Aleksandra et al.
Reduced ciprofloxacin absorption from formulations containing ciprofloxacin hyd-
rochloride when co-administered with metallic ion containing preparations has been re-
ported in a number of in vivo studies (1–9). While formation of a nonabsorbable complex
has been postulated as the interaction mechanism (1, 10–12), some authors comment that
physicochemical factors such as solubility may also play a role (4). Several authors re-
port that ciprofloxacin hydrochloride tablet dissolution is retarded in the presence of
metallic compounds, indicating that dissolution might be used as an in vitro tool for
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rofloxacin is co-administered with metallic ion contain-
ing preparations. In our previous study, physicochemical
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drug interaction simulation (11, 13). In our previous study (14), a poorly soluble complex
with a 2:1 ciprofloxacin to iron ratio was isolated from media used for ciprofloxacin hyd-
rochloride solubility and dissolution studies in the presence of ferrous sulphate. Biore-
levant dissolution data reflecting ciprofloxacin-iron interaction were obtained in a small
volume dissolution apparatus (14). In the light of the known formation of metal ion
complexes of Ca, Zn (15) and Al (16) with ciprofloxacin, it was hypothesised that such
complexes may form an impact on ciprofloxacin hydrochloride solubility and dissolu-
tion. In the present study, ciprofloxacin hydrochloride solubility in water and reactive
media containing different amounts of aluminium, calcium and zinc compounds, as well
as comparative ciprofloxacin tablet dissolution studies in the presence of different me-
tallic ions have been performed. In order to identify the nature of physicochemical inter-
actions, if any, characterisation of the solid phases collected from the dissolution vessel
following ciprofloxacin tablet dissolution in water in the presence of aluminium hyd-
roxide, calcium carbonate and zinc sulphate was made.
EXPERIMENTAL
Materials
Ciprofloxacin hydrochloride tablets (Marocen 500 mg, Hemofarm, Serbia) were pur-
chased commercially. Marocen tablets contain 500 mg of ciprofloxacin as the active in-
gredient while the other excipients are: microcrystalline cellulose, crospovidone, hydro-
xypropyl methylcellulose, macrogol 4000, magnesium stearate, maize starch, colloidal
silicon dioxide and titanium dioxide (E 171).
Ciprofloxacin hydrochloride salt was kindly donated by Hemofarm, Serbia. The in-
vestigated metallic ion containing compounds were: aluminium hydroxide (Fluka, Buchs,
Switzerland), calcium carbonate (Centrohem, Stara Pazova, Serbia), zinc sulphate, hep-
tahydrate (Sigma-Aldrich Chemie GmbH, Steinheim, Germany) and ferrous sulphate,
heptahydrate (Centrohem, Stara Pazova, Serbia).
Solubility
Ciprofloxacin hydrochloride solubility in water, without and with addition of dif-
ferent amounts of investigated metallic compounds (aluminium hydroxide, calcium car-
bonate, zinc sulphate and ferrous sulphate), was determined as described earlier by
Paroj~i} et al. (14). All determinations were performed at ambient temperature (25 °C).
Samples were continuously shaken on a laboratory shaker (Unimax 1010, Heidolph,
Schwabach, Germany) for six hours, then centrifuged and filtrated through the cellulose
nitrate membrane filter (pore size 0.45 μm; Millipore, USA), appropriately diluted and
assayed by UV-spectrophotometry (UV-Vis spectrophotometer Evolution 300, Thermo
Fisher Scientific, Madison, USA) at 276 nm. Sample pH values were monitored (pH meter-
-HANNA 9321, USA). All the solubility studies were performed in triplicate.
78
A. Stojkovi} et al.: Biopharmaceutical characterisation of ciprofloxacin-metallic ion interactions: Comparative study into the effect of
aluminium, calcium, zinc and iron on drug solubility and dissolution, Acta Pharm. 64 (2014) 77–88.
Dissolution
Dissolution studies were performed at 37 ± 0.5 °C using the mini paddle dissolution
apparatus (Erweka DT 700, Heusenstamm, Germany) at 50 rpm, using 50 mL of water as
dissolution medium, without and with addition of different amounts of aluminium hyd-
roxide, calcium carbonate, zinc sulphate and ferrous sulphate. To evaluate the influence
of different cations on ciprofloxacin dissolution, the investigated metallic compounds
were added to each vessel concomitantly with the ciprofloxacin tablet in different amounts,
corresponding to those used in solubility studies. Dissolution studies in water were per-
formed using the amounts of aluminium hydroxide (1800 mg), calcium carbonate (3400
mg) and ferrous sulphate heptahydrate (496 mg) 'equal' to the doses administered in
vivo in relevant interaction studies (2, 4). Use of the same doses of aluminium hydroxide,
calcium carbonate and ferrous sulphate as in clinical studies (2, 4) was aimed at in vitro
simulation of ciprofloxacin-metallic cation interactions observed in vivo. Amounts of zinc
sulphate used (500, 1000 and 2110 mg) corresponded to the level of this salt used in the
solubility study. All experiments were performed in triplicate. Where a solid phase was
formed during dissolution studies, it was collected at the end of the dissolution run and
dried at room temperature for further characterisation.
Solid state characterisation
Solid phases collected after the dissolution studies of ciprofloxacin hydrochloride
tablets in the presence of aluminium hydroxide, calcium carbonate and zinc sulphate
were characterised using powder X-ray diffraction (XRD), Differential Scanning Calori-
metry (DSC), Thermogravimetric Analysis (TGA) and Fourier Transform Infrared Ana-
lysis (FTIR).
Powder samples were studied by the XRD technique using a Miniflex II (Rigaku,
Tokyo, Japan) Desktop X-ray diffractometer with an Ilaskris cooling unit. The tube out-
put voltage employed was 30 kV and tube output current was 15 mA. A Cu-tube with
Ni-filter suppressing Kb radiation was used. The scanning angle ranged from 5 to 40° of
2 q scale at a step size of 0.05° per second in each case (17).
Differential scanning calorimetry (DSC) experiments were conducted using a Met-
tler Toledo DSC 821e (Mettler Toledo Ltd, Zurich, Switzerland) with a refrigerated co-
oling system (LabPlant RP-100). Nitrogen was used as a purge gas. Aluminium sample
holders were sealed with a lid and pierced to provide three vent holes. Sample volume
was sufficient to provide proper contact between the powder and the bottom of the pan,
and sample mass was 5 mg (17).
Thermogravimetric analysis (TGA) was performed using a Mettler TG 50 (Greifen-
see, Switzerland) module linked to a Mettler MT5 balance in the furnace under nitrogen
purge. Sample masses were between 5 and 12 mg and were placed into open aluminium
pans. A heating rate of 10 °C/min was implemented in all DSC and TGA measurements.
Analysis was carried out and monitored by the Mettler Toledo STARe software (version
6.10) with a Windows NT operating system. The unit was calibrated with indium and
zinc standards (17).
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FTIR spectra were recorded on a Fourier Transform Infrared Nicolet Magna IR 560
E.S.P. spectrophotometer coupled with a MCT/A detector (Thermo Electron Corporati-
on, Waltham, MA, USA). Data were acquired with the Nicolet software Omnic (version
4.1). Sixty-four scans of symmetrical interferograms were averaged and the spectrum
was calculated from 650 to 4000 cm–1 at 2 cm–1 spectral resolution. A KBr disc method
was used with 1 % (m/m) sample loading. KBr disks were prepared by direct compres-
sion under 8 bar pressure for 1 minute (17).
Quantification of zinc by inductively coupled plasma-mass spectrometry (ICP-MS)
Determination of the zinc content in the sample collected from the dissolution ves-
sel in the presence of 2110 mg zinc sulphate was performed using ICP-MS (Palo Alto,
CA, USA). A known mass of the sample was placed in a digestion vessel and then treated
with 69 % HNO3 and 30 % H2O2. The vessel was sealed and heated in a microwave
digester operating at 1000 W for 20 minutes at 200 °C. The sample was then diluted with
deionized water and the digest was analysed with ICP-MS Varian 820 (Palo Alto, CA,
USA).
Quantification of chloride and sulphate ions by photometry
Quantification of chloride and sulphate ions by photometry was performed as des-
cribed earlier by Paroj~i} et al. (14).
Statistical analysis
Differences between the amounts of ciprofloxacin dissolved in the presence of inves-
tigated metallic compounds were evaluated by one-way ANOVA (SPSS Statistics 20,
USA). Differences between the groups (i.e., the amount of ciprofloxacin hydrochloride
dissolved in the presence of aluminium hydroxide, calcium carbonate, ferrous sulphate
or zinc sulphate) were compared using the post-hoc LSD test. Probability of p < 0.05 or
less was considered significant. Double-sided confidence interval (i.e., 95 %) was used
for statistical analysis.
RESULTS AND DISCUSSION
Literature overview of ciprofloxacin bioavailability
Ciprofloxacin hydrochloride is rapidly absorbed after oral administration. Results
of a remote control capsule study (25) revealed that ciprofloxacin is predominantly ab-
sorbed in the duodenum and upper jejunum, with 78 % of dose absorbed from this gas-
trointestinal segment. Such data suggest the existence of a narrow absorption window in
the proximal intestine and indicate that potential interactions occurring after drug in-
gestion may strongly affect its bioavailability.
A literature survey of ciprofloxacin bioavailability, when administered with and
without different metallic ion containing preparations, was undertaken. The overview of
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the available data is presented in Fig. 1 where the first column represents ciprofloxacin
absolute bioavailability data obtained from a number of studies (18–23) while other
columns represent relative bioavailability (i.e., ratio of AUCs relevant to the interaction
study and absolute BA) of ciprofloxacin when co-administered with preparations con-
taining different metallic ions (1–9, 24). Relatively high variability in drug bioavailability
is evident, both in the pharmacokinetic studies following oral administration of cipro-
floxacin hydrochloride tablets alone as well as in the interaction studies in which va-
rious drug products or dietary supplements containing different metallic compounds
were co-administered. The in vivo data indicate rapid and relatively variable drug ab-
sorption with the absolute bioavailability values ranging from 52 to 90 % (average ap-
prox. 70 %). Ciprofloxacin bioavailability in the presence of different metallic compounds
was reduced to a variable extent depending mainly on the type of metallic compound/
preparation administered, its dose and dosage regimen. Ciprofloxacin absorption was
greatly impaired when it was administered with a high dose of aluminium hydroxide
(1.8 g) or aluminium/magnesium antacid (1.32 g/1.17 g and 9 g/6 g) (2, 6, 24). The
extent of ciprofloxacin absorption was reduced by approximately 40 % in the presence of
calcium compared to the control reported in specific individual studies (2, 8, 9) and by
40–80 % in the presence of different iron preparations (1, 3–5, 7). Multivitamins with zinc,
used in the studies of Kara et al. (3), contained a mixture of different metallic compo-
unds, which could have contributed to the observed interaction. Reduced bioavailability
observed in a number of in vivo studies following ciprofloxacin co-administration with
different metallic ion containing preparations may result from the reduced permeability
or reduced solubility of the interaction adduct.
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Fig. 1. Ciprofloxacin bioavailability with and without metal ion containing preparations co-admi-
nistration: summary of available literature data (1–9, 18–24). Absolute BA denotes to absolute bio-
availability of ciprofloxacin tablets; “Zn multivit, Ca, Fe, Al/Mg,” denote relative bioavailability
(i.e. ratio of AUCs relevant to the interaction study and “control”) of ciprofloxacin when co-admin-
istered with preparations containing different metallic ions; column represents the mean values ±
SD (shown as error bars) from a multiple studies represented by open circles).
Solubility study
The results of ciprofloxacin hydrochloride solubility studies in water and reactive
media containing different amounts of metallic compounds are presented in Fig. 2. Cip-
rofloxacin hydrochloride solubility in water was 42.0 ± 0.07 mg mL–1 (i.e., 109 mmol L–1;
final pH 4.04). The amount of ciprofloxacin hydrochloride in all the reactive media con-
taining metallic compounds (i.e. aluminium hydroxide and calcium carbonate suspen-
sions and ferrous sulphate and zinc sulphate solutions) was significantly reduced com-
pared to the amount of ciprofloxacin hydrochloride dissolved in water. Interaction with
calcium carbonate led to the most pronounced effect, with a 300-fold decrease in the
amount of ciprofloxacin dissolved (p = 0.001). Addition of calcium carbonate resulted in
a markedly increased pH value of investigated samples (pH > 6). In the case of zinc sul-
phate and ferrous sulphate, a similar effect on the amount of ciprofloxacin hydrochlo-
ride dissolved was observed and there was no statistically significant difference be-
tween the effects of zinc sulphate and ferrous sulphate (p = 0.845) on the amount of the
drug dissolved. The associated media pH values were in the same range (pH 2.4–3.4),
indicating that the effect observed was not just a pH related effect. Addition of insoluble
aluminium hydroxide resulted in the least effect on ciprofloxacin hydrochloride disso-
lution (p = 0.04), with a slight increase of media pH (pH 4.8).
Dissolution study
Ciprofloxacin tablet dissolution profiles in water containing different amounts of alu-
minium hydroxide, calcium carbonate, zinc sulphate and ferrous sulphate are presented
in Fig. 3a–d. Ciprofloxacin hydrochloride dissolution from the tablet in water was rapid
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Fig. 2. Ciprofloxacin hydrochloride concentration in media containing different amounts of metallic
ion containing compounds: zinc sulfate (), ferrous sulfate (), calcium carbonate () and alumi-
nium hydroxide (). Inset: theoretical pH solubility profile of ciprofloxacin with the data points
representing experimentally obtained ciprofloxacin solubility in water (closed circle refers to cipro-
floxacin base and open circle to ciprofloxacin HCl).
and almost complete (final pH 3.99). In the presence of metallic compounds, relatively fast
initial dissolution was observed, followed by the plateau phase after 10 or 20 minutes of
investigation. However, the amount of drug dissolved in the “plateau” phase differed
markedly in dependence on the type and amount of metallic compound added.
Ciprofloxacin tablet dissolution in the presence of aluminium hydroxide (Fig. 3a)
was generally not affected, irrespective of the amount of the hydroxide added (i.e., final
pH ranged from 4.4–4.9). Aluminium hydroxide did not dissolve in water and the excess
solid phase preventing tablet dissolution might be responsible for slower ciprofloxacin
dissolution from tablets observed at the highest dose of hydroxide added (i.e., 3400 mg;
media pH 4.9).
Calcium carbonate addition had the most pronounced effect on ciprofloxacin hyd-
rochloride solubility and tablet dissolution, associated with the substantial increase in
media pH. Upon the addition of poorly soluble calcium carbonate, the initially fast drug
dissolution was followed by a notable reduction in the amount of drug dissolved, reach-
ing a maximum of ~ 20 % (Fig. 3b). Ciprofloxacin dissolution profiles in the presence of
different amounts of calcium carbonate exhibited obvious phase transformation during
the first 30 minutes of investigation. In this case, the media pH value increased, resulting
in pH 7.2 in media containing 500 and 3400 mg calcium carbonate. Ciprofloxacin con-
centration in the dissolution media containing the highest dose of calcium carbonate
was 0.83 mg mL–1, which was close to the solubility of ciprofloxacin base.
Increased amounts of soluble zinc sulphate and ferrous sulphate in dissolution
media resulted in markedly reduced ciprofloxacin tablet dissolution, with 20 and 26 %
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Fig. 3. Ciprofloxacin tablet dissolution in water without (control) and with different amounts of: a)
aluminium hydroxide, b) calcium carbonate, c) zinc sulfate and d) ferrous sulfate addition.
ciprofloxacin dissolved at the highest doses of the investigated metallic compounds,
respectively. The final media pH values obtained in the presence of 500–2110 mg of zinc
sulphate (Fig. 3c) and 200–700 mg of ferrous sulphate (Fig. 3d) ranged from 3.4–3.7 and
from 3.1–3.2, respectively, indicating that the effects observed could not be attributed
solely to the medium pH value.
Solid state characterisation
Results of the powder XRD and FTIR analysis of the solid phases collected from the
dissolution vessels after performing ciprofloxacin hydrochloride tablet dissolution in
the presence of different metallic compounds are presented in Fig. 4 and 5, respectively.
The results obtained indicate that, in the case of reactive media containing aluminium
hydroxide, only excess aluminium hydroxide was found. XRD, DSC and FTIR data ob-
tained from the solid phase collected after ciprofloxacin tablet dissolution in the presen-
ce of aluminium hydroxide were similar to data reported in the literature (26, 27). This
result is consistent with the almost complete ciprofloxacin dissolution observed. Litera-
ture data report that ciprofloxacin aluminium complexes are more soluble than the parent
drug (28). Ciprofloxacin solubility and drug dissolution from the tablet in the presence
of aluminium hydroxide were generally not affected, indicating that no ciprofloxacin-
-aluminium complex was formed. The results of solid state characterisation revealed
that the solid phase that crystallized from the media containing calcium carbonate was a
hydrate of ciprofloxacin base, which is more than 400-fold less soluble when compared
to its hydrochloride salt (29). The X-ray diffractogram of the solid phase collected from
ciprofloxacin tablet dissolution in the presence of calcium carbonate was consistent with
that of the ciprofloxacin 1:3.7 hydrate (29). FTIR spectra exhibited characteristic bands at
1623, 1580 and 1380 cm–1 assigned to the ketone C=O stretch, antisymmetric and sym-
metric vibrations of the carboxylate anion, respectively, consistent with the spectra
found by Dorofeev (30). Thermal analysis of the solid phase collected from ciprofloxacin
hydrochloride tablet dissolution in the presence of calcium carbonate revealed a major
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Fig. 4. XRD scans of: a) ciprofloxacin
base, b) ciprofloxacin HCl monohyd-
rate and solid phase collected from
ciprofloxacin tablet dissolution study
in media containing: c) aluminium
hydroxide, d) calcium carbonate, e)
zinc sulfate and f) ferrous sulfate.
endothermic event at approximately 270 °C preceded by a broad endotherm at 100 °C.
The endotherm at 100 °C was accompanied by a mass loss of approximately 14.5 % and
attributed to adsorbed/crystalline water evaporation. Obvious phase transition observ-
ed in the dissolution study and caused by increasing pH media indicated formation of a
less soluble product. Having in mind the pH dependent solubility of ciprofloxacin hyd-
rochloride that precipitates at pH about 6.8, formation of the less soluble neutral/zwit-
terion ciprofloxacin base was expected.
Results of the powder XRD, FTIR and DSC analyses of the solid phase collected
from ciprofloxacin tablet dissolution in the presence of ferrous sulphate were described
in a previous study (14).
The X-ray diffractogram of the solid phase obtained from ciprofloxacin hydrochlo-
ride tablet dissolution in the presence of zinc sulphate shows peaks at ~9 and 17 2q de-
grees, the diffractogram was different from those of the ciprofloxacin base and hydro-
chloride salt (Fig. 4). Thermogravimetry of the solid phase collected from ciprofloxacin
tablet dissolution in the presence of zinc sulphate showed an 18.8 % mass loss. FTIR
scan of the collected solid phase from ciprofloxacin tablet dissolution in the presence of
zinc sulphate exhibited an absorption band at approximately 3500 cm–1, most likely of
the OH stretch vibrations of water molecules. The characteristic band for the (C=O)
vibration of carboxylic and ketone groups in ciprofloxacin hydrochloride monohydrate
were at 1709 and 1624 cm–1, respectively. Absorption bands for the (C=O) vibration of
the carboxylic and ketone groups were observed at 1722 and 1629 cm–1 and bands were
slightly shifted in comparison with ciprofloxacin hydrochloride (Fig. 5). Absorption
band for C=O vibration of the carboxylic group was very weak, probably indicating that
the COOH group was deprotonated.
Ciprofloxacin solubility and dissolution from the tablet in the presence of ferrous
sulphate and zinc sulphate were reduced to a similar extent. Initially fast drug dissolu-
tion was followed by a notable reduction in the amount of drug dissolved, indicating
formation of a new ionic species. It was found in the previous study (14) that ciproflo-
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Fig. 5. FTIR scans of: a) ciprofloxa-
cin base, b) ciprofloxacin HCl mono-
hydrate and solid phase collected
from ciprofloxacin tablet dissolution
study in media containing: c) alumi-
nium hydroxide, d) calcium carbo-
nate, e) zinc sulfate and f) ferrous
sulfate.
xacin hydrochloride interaction with ferrous sulphate resulted in the formation of a low
solubility complex with the probable chemical structure of Fe(SO4)2(Cl)2(ciprofloxacin)2
× nH2O, where n is up to 12 molecules of water. Results of the zinc assay (i.e., zinc con-
tent 4.0 %), along with FTIR analysis of the solid phase generated in the interaction me-
dia containing zinc sulphate, suggested also complex formation. A close examination of
the XRD and FTIR scans of zinc and iron complexes (presented in Figs. 4 and 5) revealed
that their structures are likely to be isotypic, implying that the two complexes should
have a very similar chemical form. Indeed, based on the chloride and sulphate content
analysis (chloride and sulphate contents were 4.5 and 11.7 %, respectively), the possible
stoichiometry of the zinc complex could be Zn(SO4)2(Cl)2(ciprofloxacin)2 × nH2O, where
n is up to 12 molecules of water. Turel et al. (15) found that the zinc complex with nor-
floxacin (nfH), (nfH3)(nfH2)[ZnCl4]Cl × H2O, was isotypic to the copper/norfloxacin
compound; thus the occurrence of isotypism for fluoroquinolone-metal complexes is not
unexpected. The zinc-ciprofloxacin adduct isolated and presented in this work is new
and its structure has been unpublished to date and is also different from the zinc-cipro-
floxacin complex with a structure of [ciprofloxacinH2]2 × [ZnCl4] × H2O isolated by
Zupan~i~ at al. (31).
New solid phases were isolated from the interaction mixtures containing relatively
high concentrations of ciprofloxacin hydrochloride and ferrous sulphate, or zinc sulphate.
These results indicate that small volume dissolution experiments may be useful for
biorelevant dissolution tests, which is in accord with the findings of other authors (32, 33).
CONCLUSIONS
Ciprofloxacin hydrochloride metallic ion in vitro interaction studies revealed that drug
solubility and dissolution were impaired to different extents in dependence on the type
of the metallic compound present. Based on the quantitative analysis and FTIR spectra,
precipitates collected after drug dissolution studies in the media containing zinc sulphate
and ferrous sulphate were identified as poorly soluble complexes. Analysis of the novel
zinc complex isolated in this work is consistent with stoichiometry of Zn(SO4)2(Cl)2(cip-
rofloxacin)2 × nH2O, where n is up to 12 molecules of water. Such data are in accord with
our earlier findings on the probable chemical structure of the ciprofloxacin-iron inter-
action product. In contrast, interaction studies with aluminium hydroxide and calcium
carbonate did not result in complex formation. Ciprofloxacin hydrochloride salt was
identified upon evaporation of the dissolution media in interaction studies with alumi-
nium hydroxide, while the interaction with calcium carbonate resulted in precipitation
of ciprofloxacin (base) hydrate. Since ciprofloxacin exhibits an absorption window in the
proximal small intestine, it may be postulated that drug co-administration with a me-
tallic compound containing preparations may result in different types of interactions
that lead to reduced ciprofloxacin hydrochloride solubility and subsequent absorption.
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